Redwood City, CA, May 7, 2025 – Osteoboost Health, Inc today announced the nationwide availability of Osteoboost, the first and only FDA-cleared prescription medical device for low bone density. Osteoboost represents a novel, protective and preventative approach to bone health at a time when tens of millions are left without…
Read more
By Laura Yecies, CEO of Osteoboost Today represents an important milestone for women’s bone health. My interest in bone health began in college, while working at a nursing home. I saw firsthand how hip fractures could change a person’s life. Years later, I watched my mother and grandmother navigate osteoporosis.…
Read more
By Michael Jaasma, PhD, Co-founder and Chief Scientific Officer at Osteoboost Health In January 2024, Osteoboost achieved a notable regulatory milestone by receiving De Novo classification from the U.S. Food and Drug Administration (FDA). This designation is significant not only because FDA approval is a rigorous process but also because…
Read more
One of the biggest challenges of aging is the loss of bone density, which too often leads to osteoporosis and serious fractures that significantly impact quality of life. Our mission with Osteoboost is to slow the process of bone loss and preserve bone density and strength, helping people live stronger,…
Read more
Almost four years ago, I had my second dexa scan and got the news that I have learned is typical: in the five years after menopause, my bone density went from normal to osteopenia. I lost 13% of my bone density in my spine. I got a weirdly chipper note…
Read more
REDWOOD CITY, CA (July 2, 2024) – Bone Health Technologies (BHT), a leading medtech innovator developing breakthrough noninvasive and drug-free solutions for low bone density, today announced the company has been awarded a fifth patent for Osteoboost—the first and only FDA-cleared prescription medical device to treat osteopenia. The patent, US…
Read more
Redwood City, CA – January 18, 2024 – Bone Health Technologies today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for OsteoboostTM, the first non-pharmacological device-based prescription treatment for postmenopausal women diagnosed with osteopenia (low bone density). Osteoboost is a wearable belt device, worn on the…
Read more
